Published in Cancer Chemother Pharmacol on January 01, 1990
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol (2000) 16.83
Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet (2001) 5.75
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst (2000) 5.62
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol (2001) 5.25
On the receiving end--patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol (1983) 4.35
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol (2002) 4.25
a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med (2000) 4.15
Management of malignant teratoma: does referral to a specialist unit matter? Lancet (1993) 3.73
Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res (1999) 3.24
Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol (2000) 3.04
Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg (2001) 2.94
Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res (1989) 2.71
High ambient temperature: a spurious cause of hypokalaemia. BMJ (1996) 2.56
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol (1998) 2.52
Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol (1997) 2.29
Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet (1991) 2.26
Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res (2000) 2.17
Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. J Natl Cancer Inst (1999) 2.15
Rural and urban differences in stage at diagnosis of colorectal and lung cancers. Br J Cancer (2001) 2.12
Therapy for testicular cancer in Central and Eastern Europe. Lancet (1990) 2.08
Rapid one step urine test for human chorionic gonadotrophin in evaluating suspected complications of early pregnancy. BMJ (1991) 2.06
Sensitivity versus specificity in melanoma imaging using iodine-123 iodobenzamide and indium-111 pentetreotide. Eur J Nucl Med (1994) 2.05
Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet (2002) 2.00
Superiority of demeclocycline over lithium in the treatment of chronic syndrome of inappropriate secretion of antidiuretic hormone. N Engl J Med (1978) 1.98
Rural factors and survival from cancer: analysis of Scottish cancer registrations. Br J Cancer (2000) 1.97
Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Ann Oncol (2000) 1.96
Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res (1996) 1.95
Risk factors and outcome of hospital-acquired acute renal failure. Clinical epidemiologic study. Am J Med (1987) 1.93
Reforming the core clerkship in internal medicine: the SGIM/CDIM Project. Society of General Internal Medicine/Clerkship Directors in Internal Medicine. Ann Intern Med (2001) 1.91
CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr Virus-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene (1996) 1.85
Factors influencing time from presentation to treatment of colorectal and breast cancer in urban and rural areas. Br J Cancer (2004) 1.80
Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J Clin Oncol (2005) 1.80
Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet (1992) 1.80
Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol (2000) 1.77
Medical audit, cancer registration, and survival in ovarian cancer. Lancet (1991) 1.73
Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol (1992) 1.73
Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy. Br J Cancer (2005) 1.71
Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer (2003) 1.70
A rapid infusion protocol is safe for total dose iron polymaltose: time for change. Intern Med J (2011) 1.70
The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party. J Clin Oncol (1992) 1.67
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer (2006) 1.66
Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol (2001) 1.62
A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res (2000) 1.59
Wortmannin and its structural analogue demethoxyviridin inhibit stimulated phospholipase A2 activity in Swiss 3T3 cells. Wortmannin is not a specific inhibitor of phosphatidylinositol 3-kinase. J Biol Chem (1995) 1.58
Changes in testicular cancer in Scotland. Eur J Cancer Clin Oncol (1987) 1.58
EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group. Eur J Cancer (1996) 1.58
Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial. J Clin Oncol (1994) 1.58
Incomplete resection of focal cortical dysplasia is the main predictor of poor postsurgical outcome. Neurology (2008) 1.57
Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res (1999) 1.57
Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol (1994) 1.56
Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol (2002) 1.55
Impact of deprivation and rural residence on treatment of colorectal and lung cancer. Br J Cancer (2002) 1.55
Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy. Eur J Cancer (1997) 1.55
Carboplatin or cisplatin? Lancet (1988) 1.53
Disulfiram modulated ROS-MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties. Br J Cancer (2011) 1.53
Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer (2001) 1.52
Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at postchemotherapy surgery. EORTC Genitourinary Tract Cancer Cooperative Group (EORTC GU Group) Eur J Cancer (1991) 1.52
Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet (2003) 1.52
Late spontaneous anterior dislocation of an intraocular lens (IOL) with the capsular bag. Eye (Lond) (2005) 1.52
Collagen corneal shields. Surv Ophthalmol (2002) 1.49
Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer (2002) 1.49
The changing role of surgery in metastatic non-seminomatous germ cell tumour. Br J Cancer (1992) 1.49
Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol (2003) 1.48
The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. Ann Oncol (2012) 1.46
Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcɛRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity. Clin Exp Allergy (2011) 1.45
Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience. Ann Oncol (2012) 1.44
Standard operating procedure for the collection of fresh frozen tissue samples. Eur J Cancer (2007) 1.43
Antiemetic therapy--where do we go from here? Ann Oncol (1993) 1.43
The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene (1995) 1.43
High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma. Cancer Chemother Pharmacol (1983) 1.42
National survey of Clerkship Directors in Internal Medicine on the competencies that should be addressed in the medicine core clerkship. Am J Med (1997) 1.41
New transtracheal bronchoalveolar lavage technique for the diagnosis of respiratory disease in sheep. Vet Rec (2005) 1.41
The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother Pharmacol (1986) 1.41
Chemotherapy for colorectal cancer. J R Soc Med (2000) 1.40
Ovarian cancer and infertility: a genetic link? Lancet (1999) 1.40
Chemotherapy of advanced malignant teratomas. Br J Cancer (1980) 1.40
5-Fluorouracil and folinic acid: interesting biochemistry or effective treatment? Br J Cancer (1989) 1.39
Suture materials and subsequent wound strength. J Obstet Gynaecol (2008) 1.39
Bilirubin interference with a salicylate assay performed on an Olympus analyser. Ann Clin Biochem (2000) 1.39
Langerhans' cells in the cervix. Am J Obstet Gynecol (1987) 1.39
Pituitary dysfunction in recently post-menopausal women. Nottingham EPIC Study Group. Clin Endocrinol (Oxf) (1997) 1.39
Systematic review of cancer treatment programmes in remote and rural areas. Br J Cancer (1999) 1.39
Bilateral testicular cancer: a preventable problem? Experience from a large cancer centre. BJU Int (2003) 1.38
Antenatal screening for gonorrhoea in Christchurch. N Z Med J (1977) 1.38
Epilepsy surgery in children with tuberous sclerosis complex: presurgical evaluation and outcome. Epilepsia (2000) 1.37
Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer (1993) 1.36
Cytotoxic-loaded albumin microspheres: a novel approach to regional chemotherapy. Br J Surg (1988) 1.36
Effect of marihuana and placebo-marihuana smoking on angina pectoris. N Engl J Med (1974) 1.34
Fluoroquinolones: place in ocular therapy. Drugs (2001) 1.34
Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer (1996) 1.33
Tissue distribution and tumour localization of 99m-technetium-labelled liposomes in cancer patients. Br J Cancer (1979) 1.32
Clinical and endoscopic features of melanoma metastases in the upper GI tract. Gastrointest Endosc (1999) 1.32